-
I Feel At Home At Manchester City –Rodri - 7 mins ago
-
Jailed breast surgeon Paterson was a nightmare - 10 mins ago
-
Ohio AG Wrong to Block Voting Amendment Based on Title: State Supreme Court - 19 mins ago
-
Lennox Lewis: Rematch lessons must be learned for AJ revenge - 21 mins ago
-
Dozens killed by heavy rains hitting Spain — MercoPress - 23 mins ago
-
Trial over £40m East Yorkshire pub car park cocaine haul starts - 24 mins ago
-
Lyle and Erik Menendez to return to court Dec. 11 - 32 mins ago
-
Man Called ‘AK Guru’ Charged With Making and Selling Illegal Machine Guns - 33 mins ago
-
Christine Brown vs. Kody Brown! Sister Wives Stars to Square Off in Court - 34 mins ago
-
RCMP searching for Regina mayoral candidate after assault charges - 36 mins ago
Mother’s relief as son gets cancer drug on NHS
A mother who was spending £11,000 every three months to pay for her son’s brain tumour medication has spoken of her relief after the drugs became available on the NHS.
Alexander Josephs, 10, has been taking the medication for the past two-and-a-half years since it was shown to slow the growth of his type of tumour.
His mother turned to crowdfunding to privately source the treatment – a combination of the drugs dabrafenib and trametinib.
The National Institute for Health and care Excellence (NICE) approved the medication in April.
‘More than we could cope with’
Alexander’s mother Rhonda Josephs, from Bromley, south-east London, said the family had to turn to crowdfunding for donations.
“Having a child with cancer, then having to raise loads of money – that was almost more than we could cope with.
“To have that financial stress lifted, I can’t put it into words.
“It just felt so strange to be able to walk past the cashier’s office and not hand over £11,000, and go to the pharmacy like any other person.”
Alexander has glioma, the most common type of brain cancer in children.
The two drugs work together by blocking the growth signal coming from the mutant BRAF protein and can slow or even stop the tumour from growing.
NICE – the body that decides which treatments should be available on the NHS – approved it for use in patients aged one and over with glioma with the genetic mutation BRAF V600E.
It followed clinical trials undertaken at Great Ormond Street Hospital.
In addition to taking the medication, Alexander has undergone three rounds of surgery and radiotherapy.
He is now in remission, but continues to take the treatment.
Some of the money raised through crowdfunding also allowed Alexander to visit Germany to have a personalised cancer vaccine, which could help prevent the disease returning.
Mrs Josephs described her son as “perfectly fit and healthy, really strong and really into sports” before his condition was discovered in 2020.
The first sign of illness was a seizure which “lasted for a really long time… it was terrifying”.
When Alexander returned to hospital three months later after another seizure, scan results revealed he had a brain tumour.
This turned out to be an aggressive glioma which had grown and spread to his spine.
Medics told the family that Alexander was in remission in January, leaving Mrs Josephs “cautiously optimistic”.
“They were words we’d waited to hear,” she added. “Alexander is getting back to his sports and he’s just becoming a normal little boy again. He’s doing remarkably well.”
‘Immense challenge’
Cameron Miller, director of strategy and external affairs at the Brain Tumour Charity, said the charity had previously funded research that helped identify BRAF mutations in brain tumours.
“When a breakthrough came following clinical trials, we worked with NICE to ensure the patient voice was heard.
“Our representatives, including a patient expert, participated in the scoping meeting and provided essential evidence to the committee meeting. So, we are delighted at this outcome.
“Yet Alexander’s struggle underscores the immense challenge of finding cures for this complex and unpredictable group of diseases.”
Mrs Josephs added: “I do feel children with brain tumours are written off and this shows they shouldn’t be.”
Source link